Ensomafusp Biosimilar Fusion Protein (CD19) for Research

Cat No.: GMP-Bios-ab-664

Pre-Made Ensomafusp Biosimilar, Fusion Protein targeting CD19: Recombinant therapeutic protein targeting B4/CVID3 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Anti-CD19 Acute leukemia is considered as the most common form of childhood malignancies. CD19 is a 95- kDa transmembrane glycoprotein which belongs to the immunoglobulin (Ig) superfamily and can act as a central positive response regulator in B cells. The CD19 has been expressed on the surface of leukemia cells in > 90% of cases with acute lymphoblastic leukemia. Moreover, it can be expressed on tumor cells of cases with both B-cell and chronic lymphocytic leukemia. Thus, CD19 antigen is an ideal target for immunotherapy of B-cell malignancies. CD19 can act as a B cell co-receptor in conjunction with both CD21 and CD81. Genetic studies show that CD19 has a role in keeping a balance between immunity and autoimmunity. Although both CD19 and CD22 have their own regulatory network, they do not modulate B cell receptor (BCR) signals independently. Antibody-based therapies targeting CD19 using anti CD19 monoclonal antibodies (mAbs) have lately been used for B-cell acute lymphoblastic leukemia as a promising new therapeutic anticancer drug.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-664-1mg 1mg 3090
GMP-Bios-ab-664-10mg 10mg
GMP-Bios-ab-664-100mg 100mg
GMP-Bios-ab-664-xmg ＞100mg



Product Details

Products Name (INN Index) Pre-Made Ensomafusp Biosimilar, Fusion Protein targeting CD19: Recombinant therapeutic protein targeting B4/CVID3
INN Name Ensomafusp
TargetCD19
FormatFusion Protein
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2021
Year Recommendedna
CompaniesRoche
Conditions Approvedna
Conditions ActiveB cell Lymphoma
Conditions Discontinuedna
Development Techna



About target - CD19

1. Protein B-lymphocyte antigen CD19

2. Gene CD19

3. Organism Homo sapiens (Human)

Function
Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens (PubMed:2463100, PubMed:1373518, PubMed:16672701).
Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca2+ stores (PubMed:9382888, PubMed:9317126, PubMed:12387743, PubMed:16672701).
Is not required for early steps during B cell differentiation in the blood marrow (PubMed:9317126).
Required for normal differentiation of B-1 cells (By similarity).
Required for normal B cell differentiation and proliferation in response to antigen challenges (PubMed:2463100, PubMed:1373518).
Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge (PubMed:9317126, PubMed:12387743, PubMed:16672701).